Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | BRAF | P15056 | 4/20 | 0.62 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.62 |
| ▸ | RAF1 | P04049 | 2/20 | 0.62 |
| ▸ | KDR | P35968 | 2/20 | 0.62 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.62 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.62 |
| ▸ | NEK2 | P51955 | 2/20 | 0.62 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.62 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.62 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.62 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.62 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 0.62 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.62 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.62 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.62 |
| ▸ | PLK4 | O00444 | 1/20 | 0.62 |
| ▸ | PIR | O00625 | 1/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.62 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL299436 | 0.87 | BRAF (0.69) | CYP3A4BRAFRIPK2RAF1KDR | |
| SCHEMBL298696 | 0.86 | CYP2C9 (0.70) | CYP3A4BRAFRIPK2RAF1KDR | |
| SCHEMBL297933 | 0.85 | CYP2C9 (0.68) | CYP3A4BRAFRIPK2RAF1KDR | |
| SCHEMBL298788 | 0.85 | CYP2C9 (0.67) | CYP3A4BRAFRIPK2RAF1KDR | |
| SCHEMBL288351 | 0.83 | BRAF (0.68) | CYP3A4BRAFRIPK2RAF1KDR | |
| SCHEMBL1821851 | 0.83 | CYP3A4 (0.65) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1818713 | 0.83 | CYP3A4 (0.69) | CYP3A4BRAFRIPK2RAF1KDR | |
| SCHEMBL288317 | 0.83 | CYP3A4 (0.78) | CYP3A4BRAFRIPK2RAF1KDR | |
| SCHEMBL1823367 | 0.82 | CYP2C19 (0.71) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1826427 | 0.82 | CYP3A4 (0.59) | CYP3A4BRAFRIPK2RAF1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | claimed |
| WO-2011063159-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-26 | — | — | WO | claimed |
| US-9617267-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617267-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2501236-B1 | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer | PLEXXIKON INC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20140288070-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140288070-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-09-25 | — | — | US | disclosed |
| US-8673928-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673928-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | disclosed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | disclosed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | disclosed |
| WO-2011063159-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, KRAS, RAF1 | CYP3A4 2604/4885BRAF 1/4885RIPK2 2102/4885 |
| US-20140288070-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, KRAS, RAF1 | CYP3A4 2604/4885BRAF 1/4885RIPK2 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.